How to buy I-Mab stock

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 185 staff and has a market cap (total outstanding shares value) of USD0.00.

I-Mab share price

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

• Key figures

Information last updated 2021-03-24.

52-week range	USD$11.28 - USD$65.94
50-day moving average	USD$56.59
200-day moving average	USD$45.68
Wall St. target price	USD$76.82
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.70

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of I-Mab by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab financials

Gross profit TTM	USD$30 million
Return on assets TTM	-27.35%
Return on equity TTM	-36.54%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$3.3 billion

TTM: trailing 12 months

Shorting I-Mab shares

There are currently 578,034 I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 19% down from 713,318 last month.

There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.

I-Mab's "short interest ratio" (SIR)

I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 334123.69942197). I-Mab's SIR currently stands at 1.73. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 1730 shares are currently held short.

However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.

Find out more about how you can short I-Mab stock.

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company's product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Frequently asked questions

• What percentage of I-Mab is owned by insiders or institutions?

  Currently 0.809% of I-Mab shares are held by insiders and 15.409% by institutions.

• How many people work for I-Mab?

  Latest data suggests 185 work at I-Mab.

• When does the fiscal year end for I-Mab?

  I-Mab's fiscal year ends in December.

• Where is I-Mab based?

  I-Mab's address is: West Tower, OmniVision, Shanghai, China, 201210

• What is I-Mab's ISIN number?

  I-Mab's international securities identification number is: US44975P1030

• What is I-Mab's CUSIP number?

  I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103